Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human umbilical cord mesenchymal stem cells (Puren Hospital Affiliated to Wuhan University of Science and Technology)
- Development stage
- Unknown
- Lead developer
- Puren Hospital Affiliated to Wuhan University of Science and Technology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Human umbilical cord mesenchymal stem cells (UC-MSCs) are an investigational cell therapy developed by Puren Hospital Affiliated to Wuhan University of Science and Technology for the treatment of COVID-19 pneumonia. This biologic therapy, evaluated in clinical trial NCT04293692, utilizes the potent anti-inflammatory and immunomodulatory properties of mesenchymal stem cells to mitigate the severe lung injury and systemic inflammation (cytokine storm) associated with SARS-CoV-2 infection. By secreting various paracrine factors, UC-MSCs are hypothesized to reduce pro-inflammatory cytokine levels, protect alveolar epithelial and endothelial cells from damage, and promote the regeneration of functional lung tissue. The therapy is typically administered via intravenous infusion.
- Other names
- umbilical cord-derived mesenchymal stem cellshUC-MSCsHuman Umbilical Cord Mesenchymal Stem Cells
Beyond the preview
Go deeper on human umbilical cord mesenchymal stem cells (Puren Hospital Affiliated to Wuhan University of Science and Technology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human umbilical cord mesenchymal stem cells (Puren Hospital Affiliated to Wuhan University of Science and Technology).